Treatment of Leiomyomata With the Selective Progesterone Receptor Modulator CDB-2914 [ulipristal].
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Ulipristal (Primary)
- Indications Uterine leiomyoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Mar 2012 Additional lead trial investigator (Lynnette K Nieman) identified as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual patient number (57) added as reported by ClinicalTrials.gov.